Systematic review of treatment intensification using novel agents for chemoradiotherapy in rectal cancer
British journal of surgery2018Vol. 105(12), pp. 1553–1572
Citations Over TimeTop 10% of 2018 papers
R Clifford, Naren Govindarajah, Jason L. Parsons, Simon Gollins, Nicholas P. West, Dale Vimalachandran
Abstract
Despite extensive research and promising preclinical studies, a definite further agent in addition to fluoropyrimidines that consistently improves response rate has yet to be found.
Related Papers
- [A case of recurrent gastric cancer showing partial response to capecitabine/CDDP after treatment with S-1/CDDP].(2012)
- → Uptake and Cost of CAPECITABINE Among Commercially Insured Colorectal Cancer Patients(2016)
- Капецитабин в сочетании с лучевой терапией при метастатическом поражении головного мозга у больных раком молочной железы(2015)
- Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States(2009)
- → Capecitabine in combination with radiotherapy for treatment of brain metastases in patients with breast cancer(2015)